Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
1. RAP-219 trial met primary endpoints with high statistical significance. 2. Patients experienced 77.8% reduction in seizures; 24% achieved seizure freedom. 3. RAP-219 will advance to Phase 3 trials in Q3 2026. 4. RAP-219 displays potential for broad adoption among epilepsy specialists. 5. Long-acting injectable formulation development is underway to improve adherence.